ArticleBioinformatics advances2025
BoKDiff: best-of-K diffusion alignment for target-specific 3D molecule generation.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Structure-based drug design (SBDD) leverages the 3D structure of target proteins to guide therapeutic development. While generative models like diffusion models and geometric deep learning show promise in ligand design, challenges such as limited protein-ligand data and poor alignment reduce their effectiveness. We introduce BoKDiff, a domain-adapted framework inspired by alignment strategies in large language and vision models that combines multi-objective optimization with Best-of-K alignment to enhance ligand generation. Results: Built on DecompDiff, BoKDiff generates diverse ligands and ranks them using a weighted score based on QED, SA, and docking metrics. To overcome alignment issues, we reposition each ligand's center of mass to match its docking pose, enabling more accurate sub-component extraction. We further incorporate a Best-of-N (BoN) sampling strategy to select optimal candidates without model fine-tuning. BoN achieves QED > 0.6, SA > 0.75, and over 35% success rate. BoKDiff outperforms prior models on the CrossDocked2020 dataset with an average docking score of -8.58 and 26% valid molecule generation rate. This is the first study to integrate Best-of-K alignment and BoN sampling into SBDD, demonstrating their potential for practical, high-quality ligand design. Availability and implementation: Code is available at https://github.com/khodabandeh-ali/BoKDiff.git.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.